First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

Nearly two-thirds (64%)  of Americans who have tried weight loss injections report the drugs as being “extremely effective” or “effective.” A pressing question for many users of GLP-1 receptor agonist ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

The results showed that people who took sotagliflozin had a 23% lower risk of heart attacks, strokes, and death from ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

The expected out-of-pocket costs for commonly used drugs like Eliquis and Ozempic have surged for Medicare beneficiaries in ...

Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ...

A new study reveals that diabetes significantly accelerates the emergence and spread of antibiotic-resistant Staphylococcus ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...